Astellas corporate venture invests in Keio University’s Heartseed
Heartseed, a spin-off of Keio University, targets iPS cell-derived cardiomyocytes for the treatment of heart insufficiency Heartseed news release, July 30, 2018
Heartseed, a spin-off of Keio University, targets iPS cell-derived cardiomyocytes for the treatment of heart insufficiency Heartseed news release, July 30, 2018
In the doctor-initiated trial, dopamine neural progenitor cells derived from allogenic iPS cells are administered to patients suffering from Parkinson’s disease. The experimental design has been developed byo Jun TAKAHASHI at CiRA of Kyoto University in collaboration with Dainippon Sumitomo Pharma. Dainippon Sumitomo Pharma news release, July 31, 2018